These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 14576372)

  • 1. Cyclooxygenase-2 inhibitors: are they really atherothrombotic, and if not, why not?
    Hankey GJ; Eikelboom JW
    Stroke; 2003 Nov; 34(11):2736-40. PubMed ID: 14576372
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR; Sperling RS; Reicin A; Gertz BJ
    Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?
    Strand V
    Lancet; 2007 Dec; 370(9605):2138-51. PubMed ID: 18156036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials.
    Kearney PM; Baigent C; Godwin J; Halls H; Emberson JR; Patrono C
    BMJ; 2006 Jun; 332(7553):1302-8. PubMed ID: 16740558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potential cardiovascular effects of COX-2 selective nonsteroidal antiinflammatory drugs.
    Fowles RE
    J Pain Palliat Care Pharmacother; 2003; 17(2):27-50. PubMed ID: 14649387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of nonsteroidal anti-inflammatory drugs in patients with cardiovascular disease: a cautionary tale.
    Amer M; Bead VR; Bathon J; Blumenthal RS; Edwards DN
    Cardiol Rev; 2010; 18(4):204-12. PubMed ID: 20539104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular complications of non-steroidal anti-inflammatory drugs.
    Fosslien E
    Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nonsteroidal anti-inflammatory drugs: cardiovascular, cerebrovascular and renal effects].
    Batlouni M
    Arq Bras Cardiol; 2010 Apr; 94(4):556-63. PubMed ID: 20498929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?
    Bing RJ; Lomnicka M
    J Am Coll Cardiol; 2002 Feb; 39(3):521-2. PubMed ID: 11823092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nonsteroidal anti-Inflammatory drugs and cardiovascular risk.
    Howard PA; Delafontaine P
    J Am Coll Cardiol; 2004 Feb; 43(4):519-25. PubMed ID: 14975457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An introduction to aspirin, NSAIDs, and COX-2 inhibitors for the primary prevention of cardiovascular events and cancer and their potential preventive role in bladder carcinogenesis: part I.
    Moyad MA
    Semin Urol Oncol; 2001 Nov; 19(4):294-305. PubMed ID: 11769881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative study to evaluate the cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients.
    Bhosale UA; Quraishi N; Yegnanarayan R; Devasthale D
    J Basic Clin Physiol Pharmacol; 2015 Jan; 26(1):73-9. PubMed ID: 24620015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective COX-2 inhibitors and risk of myocardial infarction.
    Krotz F; Schiele TM; Klauss V; Sohn HY
    J Vasc Res; 2005; 42(4):312-24. PubMed ID: 15976506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitors.
    Mukherjee D; Topol EJ
    Arthritis Res Ther; 2003; 5(1):8-11. PubMed ID: 12716442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
    Mukherjee D
    Thromb Haemost; 2006 Oct; 96(4):407-12. PubMed ID: 17003915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Update on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
    Hersh EV; Lally ET; Moore PA
    Curr Med Res Opin; 2005 Aug; 21(8):1217-26. PubMed ID: 16083531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of cardiovascular events in patients receiving celecoxib: a meta-analysis of randomized clinical trials.
    White WB; West CR; Borer JS; Gorelick PB; Lavange L; Pan SX; Weiner E; Verburg KM
    Am J Cardiol; 2007 Jan; 99(1):91-8. PubMed ID: 17196469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
    Borer JS; Simon LS
    Arthritis Res Ther; 2005; 7 Suppl 4(Suppl 4):S14-22. PubMed ID: 16168077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective cyclooxygenase-2 inhibitors for the treatment of arthritis.
    Fung HB; Kirschenbaum HL
    Clin Ther; 1999 Jul; 21(7):1131-57. PubMed ID: 10463513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.